Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Ovarian germ cell tumor
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 32 for your search:
Start Over
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Pegylated Liposomal Doxorubicin Hydrochloride and Nintedanib in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, Fallopian Tube, or Recurrent Metastatic Endometrial Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GYN10-149, NCI-2012-02106, 1011004095, 1103-09, NCT01485874
GSK2141795, Dabrafenib, and Trametinib in Treating Patients with Stage IIIC-IV Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1221, NCI-2013-01320, SWOG-S1221, NCT01902173
ATR Kinase Inhibitor VX-970 and Topotecan Hydrochloride in Treating Patients with Previously Treated Lung, Ovarian, Cervical, or Neuroendocrine Cancers
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0150, NCI-2015-01398, 346215, P142115, NCT02487095
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Phase: Phase II
Type: Treatment
Age: 10 to 69
Trial IDs: MT2005-21, NCI-2010-01700, 2006LS032, UMN-2006LS032, UMN-MT2005-21, UMN-0608M90586, NCT00432094
High-Dose Chemotherapy, Bevacizumab and Stem Cell Transplant in Treating Patients with Recurrent Germ Cell Tumors
Phase: Phase II
Type: Treatment
Age: 12 to 65
Trial IDs: 2008-0378, NCI-2011-01631, NCT00936936
PD 0332991 in Treating Patients With Refractory Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 03909, NCI-2009-01467, NCT01037790
PI3K Inhibitor BKM120 in Treating Patients With Refractory Advanced Solid Tumors That Have PIK3CA Mutations
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-211, NCI-2012-00257, NCT01501604
Metformin Hydrochloride in Preventing Relapse in Patients with Stage IIC/III/IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Treatment
Age: 19 to 79
Trial IDs: HUM00047900, NCI-2012-00384, HUM 47900, UMCC 2011.037, NCT01579812
Metformin Hydrochloride and Combination Chemotherapy in Treating Patients with Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 77
Trial IDs: UC IRB13-1235, NCI-2014-00860, NCT02122185
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, REN13120042, UPCI #10-027, NCT01345539
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Z-endoxifen Hydrochloride in Treating Patients with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0061, NCI-2013-01475, 110061, P10725, 8826, NCT01273168
Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA216-001, NCI-2011-01334, NCT01292655
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 10-115, NCI-2011-02500, CDR0000700997, 8808, NCT01366144
Combined Vaccine Therapy in Treating Patients with Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-09138, NCI-2011-00920, NCT01376505
A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 115717, NCI-2012-01219, NCT01458067
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and 0ver
Trial IDs: IMGN853-0401, NCI-2012-01561, NCT01609556
Donor Hematopoietic Stem Cell Transplant in Treating Young Patients with Relapsed or Refractory Solid Tumors or Lymphomas
Phase: Phase I
Type: Treatment
Age: 2 to 21
Trial IDs: RADIANT, NCI-2012-00588, NCT01625351
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B7401001, NCI-2014-01501, 2015-002704-84, NCT02122146
MLN0128 and Ziv-Aflibercept in Treating Patients with Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0665, NCI-2014-01107, 9585, NCT02159989
Pembrolizumab and Ziv-aflibercept in Treating Patients with Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9676, NCI-2014-01984, NCT02298959
Start Over